TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

CHEPLAPHARM

OncologyMetabolicRespiratory
Specialty

CHEPLAPHARM is a specialty pharmaceutical company focused on Oncology, Metabolic, Respiratory.

1975
Since
13
Drugs
-
Trials
12
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

ZYPREXA RELPREVV 2026-01-30
Labeling
ZYPREXA ZYDIS 2026-01-30
Labeling
ZYPREXA 2026-01-30
Labeling
ZYPREXA 2026-01-30
Labeling
XELODA 2025-10-03
Labeling
ZYPREXA RELPREVV 2025-01-22
Labeling
SEROQUEL XR 2025-01-22
Labeling
ZYPREXA ZYDIS 2025-01-22
Labeling
ZYPREXA 2025-01-22
Labeling
SEROQUEL 2025-01-22
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 25%
1 drugs
Metabolic 25%
1 drugs
Respiratory 25%
1 drugs
Immunology 25%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Sanofi big-pharma
Metabolic, Oncology, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic, Immunology
Novartis big-pharma
Oncology, Immunology, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Immunology
Merck big-pharma
Oncology, Immunology, Metabolic